Opioid maker and distributor brought to justice in New York


Central Islip, NY (AP) — A groundbreaking trial against multiple opioid manufacturers and distributors took place on Tuesday, with government lawyers accusing the company of killing and destroying the community.

The proceedings purchased by Suffolk and Nassau counties and State Attorney General Letitia James are part of a number of proceedings over the deaths of nearly 500,000 people in the last two decades.

However, this case is unique in that it covers the entire opioid supply chain and is brought to justice in front of a jury rather than a judge. The case is being heard in the Long Island Law School auditorium to accommodate multiple defendants and their lawyers.

Suffolk County lawyer Jayne Conroy said in an opening statement that people experiencing opioid addiction would try to show how pharmaceutical companies and distributors were working in the “parallel universe.” ..

“Celebrations of death and destruction in the community, and blockbuster sales and profits in the conference room,” Conroy said. by New York Times.

Purdue Pharma, like some individual members of the Sackler family, was first named in the proceedings before the company filed for bankruptcy. According to James’ office, all proceedings against Purdue, Marin Clot and the Rochester Drug Cooperative are currently passing through separate US bankruptcy courts.

Defendants in the proceedings included Endo Health Solutions and its affiliates. Teva Pharmaceuticals USA, Inc. And its affiliates. According to the law firm, Allergan Finance, LLC and its affiliates McKesson Corporation, Cardinal Health Inc., and Amerisource Bergen Drug Corporation.

According to a court document cited by The Times, the defendant states that the allegations are too broad to prove their liability.

James announced on Saturday that one defendant, Johnson & Johnson, had agreed to pay the state up to $ 230 million to stop the production or distribution of opioids in an 11-hour settlement.

Johnson & Johnson said the settlement does not admit liability or fraud and involves two prescription painkillers that were developed by a subsidiary and account for less than 1% of the market and are no longer sold in the United States.

James told reporters that after the court postponed that day, the defendants failed to comply with state law, did not manage effectively, and could not detect suspicious orders.

“They couldn’t notify or notify the appropriate authorities, and their compliance efforts were essentially non-existent,” she said in a conference call.

Posted on